https://www.finanznachrichten.de/nachrichten-2026-01/67407206-johnson-johnson-rybrevant-amivantamab-vmjw-longer-term-results-show-promising-and-durable-responses-in-difficult-to-treat-colorectal-cancer-008.htm
Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months Notable...
longer termjohnsonrybrevantamivantamabresults
https://www.pharmacytimes.com/view/amivantamab-plus-chemotherapy-reduced-risk-of-disease-progression-death-in-patients-with-nsclc
Compared to chemotherapy alone, amivantamab plus chemotherapy treatment with and without lazertinib had also demonstrated positive trends in OS and ORR in...
disease progressionamivantamabpluschemotherapyreduced
https://www.ajmc.com/view/cocoon-shows-how-prophylactic-ae-management-boosts-qol-when-treating-nsclc-with-amivantamab-plus-lazertinib
The COCOON trial reveals that prophylactic treatment reduces dermatological adverse events in NSCLC patients, enhancing their quality of life during...
cocoonshowsprophylacticaemanagement